top of page
The Professional Network for Healthcare Experts
Scotland backs UCB's Zilbrysq while NICE appraisal in England remains unresolved
The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.
nuaxia
4 days ago2 min read
UCB Expands Autoimmune Pipeline with $2.2B Candid Therapeutics Acquisition
A strategic move into bispecific antibodies as pharma races to redefine autoimmune treatment through targeted immune cell depletion and next-generation T cell engagers
nuaxia
May 52 min read
bottom of page